Karen J Wilson

Director Karen J Wilson buys 10,100 shares at avg $1.76 in June; stock now at $1.92, -75.8% from 52-week high.

Karen J Wilson, a director at Serina Therapeutics, made 2 separate purchases totaling 10,100 shares for $17,749.50 on June 11–12, 2026, establishing an initial position at a blended average price of $1.76. The stock has since appreciated to $1.92 (+17.1% over 30 days), but remains -75.8% from its 52-week high of $7.92 and sits in a deeply depressed valuation range. The company is unprofitable with net income of -$6,898,000 and zero revenue in the latest quarter, though it reported +132.1% annual revenue growth year-over-year. Wilson's prior same-ticker purchases (May 21–22) are not yet measurable at the 90-day mark, and her cross-ticker track record of 2 prior buys provides limited historical context for assessing timing accuracy. This filing documents a director's entry into a position in a pre-revenue biotech-stage company trading near historical lows, but the lack of measurable prior outcomes and the company's fundamentally distressed financial state limit confidence in interpreting the significance of this acquisition.

Director Karen J Wilson purchases 20,000 shares (20.0K shares) for $37,000.00 across two transactions at Serina Therapeutics (SER), establishing first holding.

Karen J Wilson, a Director at Serina Therapeutics, made 2 purchases totaling 20,000 shares for $37,000.00, establishing an initial stake in the company. The purchases occurred at $1.77 on 2026-05-21 and $1.93 on 2026-05-22, with a blended average price of $1.85. This transaction warrants attention given the company's financial profile: net income of $-6.9M in the most recent period and full-year unprofitability, though revenue growth of 132.1% year-over-year indicates accelerating top-line performance. A director purchasing shares for the first time creates a change in insider positioning at a company in growth phase but not yet profitable, meriting investor review of the acquisition's strategic rationale.